Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy

Summary. We treated 47 adult patients with de novo myelodysplastic syndrome (MDS) by an anthracycline‐AraC regimen. Median age was 54, and M/F 1·3. At diagnosis, 26 patients had refractory anaemia with an excess of blasts in transformation (RAEB‐T) three had refractory anaemia (RA). 11 had refractory anaemia with excessive blasts (RAEB) and seven had chronic myelomonocytic leukaemia (CMML). Treatment was started within 3 months of diagnosis in 30 patients, and after more than 3 months in the 17 remaining patients. At the onset of treatment, 16 patients had progressed to acute myeloid leukaemia (AML).

[1]  R. Storb,et al.  Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. , 1990 .

[2]  L. Robison,et al.  Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients , 1989, Cancer.

[3]  S. Nimer,et al.  Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[5]  R. Gray,et al.  AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial , 1989, British journal of haematology.

[6]  K. Miyazono,et al.  Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. , 1989, The American journal of medicine.

[7]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[8]  P. Fenaux,et al.  Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases. , 1988, Blut.

[9]  A. Ganser,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. , 1989, Blood.

[10]  D. Oscier.  5 Myelodysplastic syndromes , 1987 .

[11]  R. Simon,et al.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Levin Eg,et al.  Secondary myelodysplastic syndromes and leukaemias. , 1986 .

[13]  R. Larson,et al.  High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study , 1986, American journal of hematology.

[14]  G. Tricot,et al.  The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes , 1986, British journal of haematology.

[15]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[16]  A. Zander,et al.  Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP) , 1981 .

[17]  J. Armitage,et al.  Effect of chemotherapy for the dysmyelopoietic syndrome. , 1981, Cancer treatment reports.

[18]  H. Thaler,et al.  Morphological Classification, Response to Therapy, and Survival in 263 Adult Patients With Acute Nonlymphoblastic Leukemia , 1980 .

[19]  R. Mertelsmann,et al.  Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. , 1980, Blood.

[20]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .